Current Report Filing (8-k)
August 06 2020 - 04:06PM
Edgar (US Regulatory)
0001425205 false 0001425205 2020-08-06
2020-08-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act
of 1934
Date of Report (date of earliest event reported):
August 6, 2020
IOVANCE BIOTHERAPEUTICS, INC.
(Exact Name of Registrant as Specified in Charter)
|
Delaware |
|
(State of Incorporation) |
|
|
|
001-36860 |
|
75-3254381 |
|
Commission File Number |
|
(I.R.S. Employer Identification No.) |
|
|
|
|
|
999 Skyway Road,
Suite 150 |
|
|
|
San Carlos,
California |
|
94070 |
|
(Address of Principal Executive Offices) |
|
(Zip Code) |
|
|
|
|
|
(650)
260-7120 |
|
(Registrant’s Telephone Number, Including Area Code) |
|
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
¨ |
Written communications pursuant to
Rule 425 under the Securities Act
(17 CFR 230.425). |
|
¨ |
Soliciting material pursuant to
Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12). |
|
¨ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b)). |
|
¨ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c)). |
Indicate
by check mark whether the registrant is an emerging growth company
as defined in as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter). Emerging growth
company
¨
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
|
Common stock, par value $0.000041666 per share |
IOVA |
The Nasdaq Stock Market, LLC |
| |
Item 2.02. |
Results of Operations and Financial Condition. |
On August 6, 2020, Iovance Biotherapeutics, Inc. (the “Company”)
issued a press release announcing its financial results for the
quarter ended June 30, 2020 and an update on recent developments. A
copy of that press release is furnished as Exhibit 99.1.
The information furnished under this Item 2.02, including the
accompanying Exhibit 99.1, shall not be deemed to be “filed” for
the purposes of Section 18 of the Securities Exchange Act of 1934
(the “Exchange Act”), or otherwise subject to the liability of such
section, nor shall such information be deemed to be incorporated by
reference in any subsequent filing by the Company under the
Securities Act of 1933, as amended, or the Exchange Act, regardless
of the general incorporation language of such filing, except as
specifically stated in such filing.
| |
Item 9.01. |
Financial Statements and Exhibits. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this Report to be signed on
its behalf by the undersigned hereunto duly authorized.
| Date: August 6, 2020 |
IOVANCE BIOTHERAPEUTICS,
INC. |
| |
|
| |
|
| |
By: |
/s/ MARIA FARDIS |
| |
|
Maria Fardis, Chief Executive
Officer |
| |
|
